163 related articles for article (PubMed ID: 11495817)
21. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
22. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
23. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
Des Guetz G; De Mestier P; Pierga JY
J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
[TBL] [Abstract][Full Text] [Related]
24. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
25. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
26. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
27. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
28. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
29. [Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia].
Ohnisi K
Rinsho Ketsueki; 2002 Apr; 43(4):235-8. PubMed ID: 12043198
[No Abstract] [Full Text] [Related]
30. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
31. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
32. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
33. [Clinical studies with imatinib in 2004].
Eckhardt S
Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
[TBL] [Abstract][Full Text] [Related]
34. [Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].
Mayer J
Vnitr Lek; 2002 Jan; 48(1):45-9. PubMed ID: 11852587
[TBL] [Abstract][Full Text] [Related]
35. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
36. SRCircumventing imatinib resistance.
Deininger MW; Druker BJ
Cancer Cell; 2004 Aug; 6(2):108-10. PubMed ID: 15324693
[TBL] [Abstract][Full Text] [Related]
37. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
38. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Druker BJ; Lydon NB
J Clin Invest; 2000 Jan; 105(1):3-7. PubMed ID: 10619854
[No Abstract] [Full Text] [Related]
39. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
40. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]